Navigation Links
Cystic Fibrosis Foundation funds Marshall research
Date:3/28/2011

HUNTINGTON, W.Va. The Cystic Fibrosis Foundation has awarded a Marshall University scientist a two-year, $194,400 grant.

The grant to Dr. Hongwei Yu, professor in the Department of Biochemistry and Microbiology at the university's Joan C. Edwards School of Medicine, will help further his lab's work to explore the factors that control the overproduction of mucus in the lungs of cystic fibrosis (CF) patients.

According to Yu, chronic bronchial pneumonia caused by the bacterium Pseudomonas aeruginosa is a life-threatening condition for patients with CF.

"During these infections in CF patients, the bacterium is capable of producing copious amounts of alginatea thick, sugar-like polymer that plugs the airways, making breathing difficult," he said. "The alginate also helps form a thick, slimy 'biofilm' around the colonies of bacteria, protecting them from the body's immune defense mechanisms and making antibiotic treatment less effective."

Yu said the long-range goal of his research is to better understand the mechanisms of how this bacterium regulates production of the alginate biofilms in order to develop a more effective treatment option to inhibit or suppress the formation of alginate biofilms in the lungs of CF patients.

"For this project, we will be accessing the relevance of two newly identified proteins that act as alginate regulators. Once the mechanisms controlling alginate production are fully understood, it may be possible to improve treatment of these bacterial infections in CF patients by modulating or suppressing that production," he added.

Dr. John Maher, Marshall's vice president for research, congratulated Yu and praised him and his team for obtaining the grant.

"Dr. Yu's work is an excellent example of the vital research here at Marshall University that can affect the health and welfare of people everywhere. Research in his lab has the potential to have a real impact on the quality of life for people with cystic fibrosis," said Maher.

Maher also noted that Yu's research has had a regional economic development impact, saying his work has led to a patent and the development of Progenesis Technologies LLC, a West Virginia-based biotech research and development company. A second patent is pending.


'/>"/>

Contact: Ginny Painter
ginny.painter@marshall.edu
30-474-611-964
Marshall University Research Corporation
Source:Eurekalert  

Related biology news :

1. Pig model of cystic fibrosis improves understanding of disease
2. Breakthrough on cystic fibrosis 1 step closer as new research alliance formed
3. Women with polycystic ovary syndrome may be more vulnerable to BPA
4. Common diabetes drug may halt growth of cysts in polycystic kidney disease
5. 1 step closer to a drug treatment for cystic fibrosis, MU professor says
6. Drug may treat cystic fibrosis, other diseases caused by nonsense mutations, UAB researcher says
7. Research project yields better understanding of the defective protein that causes cystic fibrosis
8. Cystic fibrosis testing -- next steps
9. Two-pronged model could help foil tough cystic fibrosis infections
10. Nanoemulsion potent against superbugs that kill cystic fibrosis patients
11. New test promises quicker, more accurate evaluation for cystic fibrosis patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cystic Fibrosis Foundation funds Marshall research
(Date:6/22/2016)... , June 22, 2016  The American College of Medical ... Show Executive Magazine as one of the fastest-growing trade ... 25-27 at the Bellagio in Las Vegas ... highest percentage of growth in each of the following categories: ... companies and number of attendees. The 2015 ACMG Annual Meeting ...
(Date:6/21/2016)... , June 21, 2016 NuData Security announced ... new role of principal product architect and that ... director of customer development. Both will report directly ... officer. The moves reflect NuData,s strategic growth in ... to high customer demand and customer focus values. ...
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the ... the Dow Jones Industrial Average edged 0.27% lower to finish ... 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... ). Learn more about these stocks by accessing their free ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
(Date:6/22/2016)... Cell Applications, Inc. and StemoniX announced ... up to one billion human induced pluripotent stem ... These high-quality, consistent stem cells enable researchers to ... more time doing meaningful, relevant research. This achievement ... process that produces affordable, reliable HiPSC for life ...
Breaking Biology Technology: